bluebird bio, Inc (BLUE)

Etorro trading 970x250
bluebird bio, Inc (BLUE) Logo

About bluebird bio, Inc

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company’s product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has collaboration and license agreements with Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc., Novartis Pharma AG, Orchard Therapeutics Limited, Medigene AG, Novo Nordisk A/S, Forty Seven, Inc., Gritstone Oncology, Inc., Magenta Therapeutics, Inc., the Seattle Children’s Research Institute, University of North Carolina, and the Fred Hutchinson Cancer Research Center. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts. Address: 60 Binney Street, Cambridge, MA, United States, 02142

bluebird bio, Inc News and around…

Latest news about bluebird bio, Inc (BLUE) common stock and company :

4 Biotech Stocks To Watch This Week
22 Nov, 2021 FinancialContent
12 Health Care Stocks Moving In Monday's Pre-Market Session
22 Nov, 2021 FinancialContent

Gainers iSpecimen (NASDAQ:ISPC) stock rose 31.09% to $6.45 during Monday's pre-market session. The company's ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
22 Nov, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, traders! We're getting right into the week with a breakdown of the biggest pre-market stock movers for Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

Bluebird Bio's Thalassemia Gene Therapy Under Priority Review With FDA
22 Nov, 2021 FinancialContent

TheFDA has acceptedBluebird bio Inc's(NASDAQ: BLUE) marketing application for betibeglogene autotemcel ...

bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions
22 Nov, 2021 FinancialContent

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for betibeglogene autotemcel (beti-cel) for priority review. Beti-cel is a potentially transformative gene therapy for adult, adolescent and pediatric patients with β-thalassemia across all genotypes who require regular red blood cell (RBC) transfusions. If approved, beti-cel will be the first one-time treatment that addresses the underlying genetic cause of disease for patients living with β-thalassemia in the U.S.—offering an alternative to regular RBC transfusions and iron chelation therapy. The agency has set a Prescription Drug User Fee Act (PDUFA) goal date of May 20, 2022.

Better Buy: Vertex Pharmaceuticals vs. CRISPR
20 Nov, 2021 FinancialContent

The companies are collaborating on a potential blockbuster.

After split, bluebird bio's new CEO looks to 'regain confidence'
17 Nov, 2021 Yahoo! Finance

"Regaining confidence and credibility is something that I'm very focused on," bluebird bio CEO Andrew Obenshain told the Business Journal. "The only thing I can do in this circumstance is meet the deliverables I say I'm going to meet."

AavantiBio Further Enhances Leadership Team with Appointment of Jenny Marlowe, Ph.D. as Chief Scientific Officer
16 Nov, 2021 FinancialContent

AavantiBio (“the Company”), a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Jenny Marlowe, Ph.D. as Chief Scientific Officer. Dr. Marlowe will be responsible for leading AavantiBio’s scientific research and preclinical development. She will also serve as a key member of the company’s executive leadership team as AavantiBio seeks to advance its diversified pipeline of gene therapies in areas of significant unmet medical need.

Novo Nordisk (NVO) Gets Positive CHMP Opinion for Wegovy
12 Nov, 2021 Yahoo! Finance

The CHMP gives a positive opinion on, and recommends approval to Novo Nordisk's (NVO) Wegovy for chronic weight management in adults with obesity.

XBI, CCXI, OCGN, BLUE: Large Inflows Detected at ETF
10 Nov, 2021 FinancialContent

Symbols mentioned in this story: XBI, CCXI, OCGN, BLUE Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..

64 Biggest Movers From Yesterday
09 Nov, 2021 FinancialContent

Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares jumped 219% to close at $10.40 on Monday after the company announced ...

Why Bluebird Bio Stock Plunged Today
08 Nov, 2021 FinancialContent

Two analysts downgraded the biotech stock.

Market Rally Continues as Dow Nabs Intraday Highs
08 Nov, 2021 FinancialContent

S&P 500 Index and Nasdaq Composite are sporting modest gains, with the Dow locking in another fresh intraday high.

38 Stocks Moving In Monday's Mid-Day Session
08 Nov, 2021 FinancialContent

Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares climbed 129.8% to $7.49 after the company announced the launch of its ...

12 Health Care Stocks Moving In Monday's Intraday Session
08 Nov, 2021 FinancialContent

Gainers PetVivo Holdings (NASDAQ:PETV) shares increased by 27.75% to $4.51 during Monday's regular session. As of 11:30 EST, this ...

Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021
08 Nov, 2021 FinancialContent

Upgrades For Nektar Therapeutics (NASDAQ:NKTR), Benchmark upgraded the previous rating of Hold to Buy. Nektar ...

92 Biggest Movers From Friday
08 Nov, 2021 FinancialContent

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public ...

Could The bluebird bio, Inc. (NASDAQ:BLUE) Ownership Structure Tell Us Something Useful?
07 Nov, 2021 Yahoo! Finance

If you want to know who really controls bluebird bio, Inc. ( NASDAQ:BLUE ), then you'll have to look at the makeup of...

12 Health Care Stocks Moving In Friday's Intraday Session
05 Nov, 2021 FinancialContent

Gainers Chinook Therapeutics (NASDAQ:KDNY) shares increased by 28.75% to $15.76 during Friday's regular session. ...

64 Stocks Moving In Friday's Mid-Day Session
05 Nov, 2021 FinancialContent

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 ...

12 Health Care Stocks Moving In Friday's Pre-Market Session
05 Nov, 2021 FinancialContent

Gainers Ontrak (NASDAQ:OTRK) shares rose 21.82% to $11.78 during Friday's pre-market session. The market value of ...

Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates
05 Nov, 2021 Yahoo! Finance

Bluebird (BLUE) delivered earnings and revenue surprises of -7.72% and -59.37%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress
05 Nov, 2021 FinancialContent

bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the third quarter ended September 30, 2021.

Cambridge gene therapy firm bluebird bio to move to Somerville
05 Nov, 2021 Yahoo! Finance

The company split into two earlier this year, and the half that's keeping the original name will occupy 61,000 square feet at 455 Grand Union Blvd. by spring 2022.

bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row  
05 Nov, 2021 FinancialContent

bluebird bio, Inc. (NASDAQ: BLUE) announced today that it has signed a long-term lease with Federal Realty (Federal) to establish a biotech hub at Assembly Row. The 61,000 square foot facility to be located at 455 Grand Union Blvd. in Somerville is designed to meet the changing needs of bluebird bio’s business, including its dedicated focus on gene therapies for severe genetic diseases following the recent spinoff of its oncology portfolio.

bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row
05 Nov, 2021 Yahoo! Finance

CAMBRIDGE, Mass., November 05, 2021--bluebird bio, Inc. (NASDAQ: BLUE) announced today that it has signed a long-term lease with Federal Realty (Federal) to establish a biotech hub at Assembly Row. The 61,000 square foot facility to be located at 455 Grand Union Blvd. in Somerville is designed to meet the changing needs of bluebird bio’s business, including its dedicated focus on gene therapies for severe genetic diseases following the recent spinoff of its oncology portfolio.

28 Stocks Moving in Friday's Pre-Market Session
05 Nov, 2021 FinancialContent

Gainers ReWalk Robotics Ltd. (NASDAQ: RWLK) rose 65.8% to $2.14 in pre-market trading after the company announced its ReBoot ...

Bluebird bio completes spinout of oncology business 2seventy bio
04 Nov, 2021 Yahoo! Finance

The oncology unit is now its own, publicly traded company, called 2seventy bio, named for what CEO Nick Leschly contends is "the maximum speed of human thought."

bluebird bio to Present New Gene Therapy Data at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
04 Nov, 2021 FinancialContent

bluebird bio, Inc. (Nasdaq: BLUE) today announced that new data from its lentiviral vector (LVV) gene addition programs for patients with β-thalassemia (beta-thal) who require regular red blood cell (RBC) transfusions and sickle cell disease will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 11-14, 2021, at the Georgia World Congress Center in Atlanta, Georgia, and virtually.

bluebird bio Completes Planned Business Separation
04 Nov, 2021 FinancialContent

bluebird bio, Inc. (NASDAQ: BLUE) today announced the company has completed the tax-free spin-off of its oncology programs and portfolio into 2seventy bio, Inc., an independent, publicly-traded company. bluebird bio will continue its work focused on severe genetic disease, with three near-term opportunities to bring transformative gene therapies to patients and their families in the U.S. 2seventy will begin regular-way trading on the NASDAQ under the stock ticker symbol “TSVT” on November 5, 2021. bluebird bio will continue to trade under the stock ticker symbol “BLUE.”

bluebird bio, Inc (BLUE) is a NASDAQ Common Stock listed in , ,

970x250